The Prevalence Of Musculoskeletal Conditions In The U.K. In 2017 Fueling Growth Of The Europe Allogeneic Human Chondrocyte Market

Growing cases of falls and knee cartilage injuries is a prime factor that is expected to propel the growth of the Europe allogeneic human chondrocyte market over the forecast period. According to the article published in the British Medical Journal (BMJ Journal) February 2020, the incidence of falls in European countries were as follows in 2017: in the Western European region, 13,840 per 100,000 population seek medical treatment for a fall-related injury, of which 7,594/100,000 are from Greece and 19,796 are from Norway. Moreover, growing cases of musculoskeletal system disorders are again fostering the growth of the market. According to the State of Musculoskeletal Health, 2019 report by the Versus Arthritis, the prevalence of musculoskeletal conditions in the U.K. in 2017.

On the other hand, the high cost of the research & development which significantly affect the development process is expected to hinder the g

Key players engaged in the Europe allogeneic human chondrocyte market are Kolon TissueGene, Inc. and ISTO Technologies Inc.

Allogeneic Human Chondrocyte (AHCC) therapy is an alternative form of treatment for osteoarthritis. It is considered a tissue-based approach and not a medication. In contrast to the traditional approach of administration of steroids or non-steroidal anti-inflammatory drugs (NSAIDs), Allogenec (AHCC) uses stem cells taken from the bone marrow. The procedure is done by needleless puncture and culturing of bone marrow that provides stem cells for therapeutic transplant. European researchers have conducted many clinical trials on the allogeneic human chondrocyte and results indicate the effectiveness of this emerging therapy in reducing pain and disability in patients. The allogeneic cells are capable of producing healthy cartilage similar to that found in the body. Recent research on allogeneic cell therapies also indicates that they provide long-lasting effects and delay osteoarthritis symptoms in comparison with steroidal or non-steroid methods. The allogeneic cell therapies also reduce joint swelling and stiffness and restore normal range of motion.

Allogeneic Human Chondrocyte is being used in the clinical trial phase by several pharmaceutical companies, but it is not yet approved for marketing in the market. This is because the clinical trial phase requires an adequate number of patients to determine the safety and effectiveness of the procedure. For this reason, some companies postpone the start of the allogenic cell therapy project. As more clinical studies are conducted and data on the allogeneic human chondrocyte's benefits become better understood, these companies will most likely conduct the allgenic therapy.